RE: Pfizer bailing on animal healthLots of companies are returning to core business, and terminating non-core work even if potentially profitable (since the core development would also be profitable).
Did Pfizer give a reason for terminating? Anybody know someone at Pfizer?
We have to balance:
a) ONC's human Phase 1 results that showed efficacy (partial and complete tumor regression), though we don't know the exact percentages yet; versus
b) Pfizer terminating for unknown reasons, which may or may not be an indication of the efficacy.
Logically, partial and complete tumor regression in humans should be the more convincing argument for efficacy. We just don't have the details and so can't evaluate the percentage of efficacy yet.
(However, logic does not always govern the stock price.)